TABLE 4.
Empiric antimicrobial therapy for anaerobic bacteremia NB-PC cohorta
| Empiric antimicrobial therapy |
Organism (no. of isolates) identified by conventional methods | |
|---|---|---|
| Prior to BioFire BCID | After BioFire BCID and before final cultures and susceptibility determinations | |
| Monotherapy | ||
| TZP | TZP | Bacteroides fragilis |
| None | TZP | Aeromonas spp. |
| ATM | ATM | Bacillus coagulans |
| VAN+azithromycin | CRO | Bacteroides fragilis |
| Combination therapy | ||
| TZP regimen | TZP regimen | Bacteroides thetaiotaomicron (1), Bacteroides fragilis (1), Anaerococcus prevotii (1), Pediococcus pentosaceus (1) |
| TZP+MTZ regimen | TZP+MTZ regimen | Bacteroides fragilis (3), Bacteroides thetaiotaomicron (1) |
| MEM+MTZ | MEM+MTZ | Desulfovibrio desulfuricans (1) |
| CIP | MEM+MTZ regimen | Clostridium citroniae (1) |
| Sulfamethoxazole-trimethoprim | MTZ regimen | Parabacteroides distasonis (1) |
| CRO+MTZ | MTZ regimen | Bacteroides vulgatus (1) |
| MTZ+VAN regimen | MTZ+VAN regimen | Clostridium clostridioforme (1) |
| None | SAM+clindamycin regimen | Peptoniphilus asaccharolyticus (1) |
| MEM regimen | CRO+VAN | Fusobacterium spp. (1) |
| None | CRO+CIP | Anaerococcus tetradius (1) |
a
TZP, piperacillin-tazobactam; ATM, aztreonam; VAN, vancomycin; CRO, ceftriaxone; MTZ, metronidazole; MEM, meropenem; CIP, ciprofloxacin; SAM, ampicillin-sulbactam.